Pharmacological characterization of ATPM [(-)-3-amino- Thiazolo[5,4-b]-N- cyclopropylmethylmorphinan hydrochloride], a novel mixed κ-agonist and μ-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 306-313

  Wang, Yu Jun ^a   Tao, Yi Min ^b   Li, Fu Ying ^b   Wang, Yu Hua ^b   Xu, E Jun ^b   Chen, Jie ^b   Cao, Ying Lin ^a   Chi, Zhi Qiang ^b   Neumeyer, John L ^c   Zhang, Ao ^b   Liu, Jing Gen ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO THIAZOLO(5,4 B)N CYCLOPROPYLMETHYLMORPHINAN HYDROCHLORIDE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINAN DERIVATIVE; MORPHINE; MU OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; HEROIN DEPENDENCE; HOT PLATE TEST; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SEDATION; TREATMENT DURATION;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ABDOMINAL MUSCLES; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HEROIN DEPENDENCE; HOT TEMPERATURE; MALE; MICE; MORPHINANS; MORPHINE; PAIN MEASUREMENT; POSTURAL BALANCE; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SELF ADMINISTRATION;

EID: 63849320568     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142802     Document Type: Article

References (39)

1. Archer S, Glick SD, and Bidlack JM (1996) Cyclazocine revisited. Neurochem Res 21:1369-1373.
2. Bhargava HN, Gulati A, and Ramarao P (1989) Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord. J Pharmacol Exp Ther 251:21-26.
3. Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, and Mello NK (2003) Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28:1125-1139.
4. Butelman ER, France CP, and Woods JH (1993) Apparent pA2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther 264:145-151.
5. Crawford CA, McDougall SA, Bolanos CA, Hall S, and Berger SP (1995) The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology (Berl) 120:392-399.
6. Davis RE, Callahan MJ, Dickerson M, and Downs DA (1992) Pharmacologic activity of CI-977, a selective kappa opioid agonist, in rhesus monkeys. J Pharmacol Exp Ther 261:1044-1049.
7. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274-5278.
8. Emmerson PJ, Liu MR, Woods JH, and Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637.
9. Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T, Saitoh A, Suzuki T, Narita M, Tseng L, et al. (1999) Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist. Life Sci 65:1685-1694.
10. France CP, Medzihradsky F, and Woods JH (1994) Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 268:47-58.
11. Glick SD, Maisonneuve IM, Raucci J, and Archer S (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681:147-152.
12. He L, Fong J, von Zastrow M, and Whistler JL (2002) Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell 108:271-282.
13. Kamei J, Zushida K, Ohsawa M, and Nagase H (2000) The antinociceptive effects of endomorphin-1 and endomorphin-2 in diabetic mice. Eur J Pharmacol 391:91-96.
14. Kuzmin AV, Semenova S, Gerrits MA, Zvartau EE, and Van Ree JM (1997) Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self- administration in drug-naive rats and mice. Eur J Pharmacol 321:265-271.
15. Maisonneuve IM, Archer S, and Glick SD (1994) U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181:57-60.
16. Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, and Bidlack JM (2005) Characterization of a novel bivalent morphinan possessing kappa agonist and mu agonist/antagonist properties. J Pharmacol Exp Ther 315:821-827.
17. Mello NK, Mendelson JH, Bree MP, and Lukas SE (1990) Buprenorphine and naltrexone effects on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 254:926-939.
18. Mello NK and Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286:812-824.
19. Mello NK and Negus SS (2000) Interactions between kappa opioid agonists and cocaine: preclinical studies. Ann NY Acad Sci 909:104-132.
20. Negus SS and Mello NK (2002) Effects of mu-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of mu-agonist efficacy. J Pharmacol Exp Ther 300:1111-1121.
21. Negus SS, Mello NK, Portoghese PS, and Lin CE (1997) Effects ofkappa opioids on cocaine self-administration byrhesus monkeys. JPharmacol ExpTher282:44-55.
22. Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, and Mello NK (2000a) Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. J Med Chem 43:114-122.
23. Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, and Bidlack JM (2001) Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg Med Chem Lett 11:2735-2740.
24. Neumeyer JL, Mello NK, Negus SS, and Bidlack JM (2000b) Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharm Acta Helv 74:337-344.
25. Portoghese AS, Lipkowski AW, and Takemori AE (1987) Bimorphinans as highly selective, potent kappa opioid receptor antagonists. J Med Chem 30:238-239.
26. Saitoh A, Yoshikawa Y, Onodera K, and Kamei J (2005) Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychop-harmacology (Berl) 182:327-334.
27. Schenk S, Partridge B, and Shippenberg TS (1999) U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug- seeking. Psychopharmacology (Berl) 144:339 -346.
28. Schenk S, Partridge B, and Shippenberg TS (2000) Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl) 151:85-90.
29. Shippenberg TS, LeFevour A, and Heidbreder C (1996) kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J Pharmacol Exp Ther 276:545-554.
30. Suzuki T, Izumimoto N, Takezawa Y, Fujimura M, Togashi Y, Nagase H, Tanaka T, and Endoh T (2004) Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions. Brain Res 995:167-175.
31. Suzuki T, Shiozaki Y, Masukawa Y, Misawa M, and Nagase H (1992) The role of mu-and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 58:435-442.
32. TakemoriAE,LohHH, andLeeNM(1992) SuppressionbydynorphinA-(1-13)of the expression of opiate withdrawal and tolerance in mice. Eur J Pharmacol 221:223-226.
33. Tallarida RJ and Murray RB (1986) Manual ofPharmacologic Calculations with Computer Programs, 2nd ed, Springer Verlag, New York.
34. Tao YM, Li QL, Zhang CF, Xu XJ, Chen J, Ju YW, Chi ZQ, Long YQ, and Liu JG (2008) LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. Eur J Pharmacol 584:306 -311.
35. Tsuji M, Yamazaki M, Takeda H, Matsumiya T, Nagase H, Tseng LF, Narita M, and Suzuki T (2000) The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur J Pharmacol 394:91-95.
36. Ukai M, Mizutani M, and Kameyama T (1994) Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice. Nihon Shinkei Seishin Yakurigaku Zasshi 14:153-159.
37. Yamamoto T, Ohno M, and Ueki S (1988) A selective kappa-opioid agonist, U-50,488H, blocks the development oftolerance to morphine analgesia in rats. Eur J Pharmacol 156:173-176.
38. Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, and Neumeyer JL (2004) 2-aminothiazole-derived opioids: bioisosteric replacement of phenols. J Med Chem 47:1886-1888.
39. Zhou W, Zhang F, Tang S, Liu H, Gu J, and Yang G (2005) The dissociation of heroin-seeking patterns induced by contextual, discriminative, or discrete conditioned cues in a model of relapse to heroin in rats. Psychopharmacology (Berl) 181:197-206.